<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The CRYSTAL and OPUS randomised clinical trials demonstrated that adding cetuximab to first-line chemotherapy in patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) significantly improved treatment outcome compared with chemotherapy alone </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this pooled analysis was to further investigate these findings in patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> using extended survival data and following an enhancement in the ascertainment rate of KRAS and BRAF <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutation status from these studies </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Pooled individual patient data from each study were analysed for overall survival (OS), progression-free survival (PFS) and best overall response rate (ORR) in patients evaluable for KRAS and BRAF mutation status </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment arms were compared according to mutation status using log-rank and Cochran-Mantel-Haenszel tests </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In 845 patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> adding cetuximab to chemotherapy led to a significant improvement in OS (hazard ratio [HR] 0.81; p=0.0062), PFS (HR 0.66; p&lt;0.001) and ORR (odds ratio 2.16; p&lt;0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>BRAF mutations were detected in 70/800 evaluable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences were found in outcome between the treatment groups in these patients </plain></SENT>
<SENT sid="7" pm="."><plain>Prognosis was worse in each treatment arm for patients with BRAF <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> mutations compared with those with BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Analysis of pooled data from the CRYSTAL and OPUS studies confirms the consistency of the benefit obtained across <z:hpo ids='HP_0000001'>all</z:hpo> efficacy end-points from adding cetuximab to first-line chemotherapy in patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> mCRC </plain></SENT>
<SENT sid="9" pm="."><plain>BRAF mutation does not appear to be a predictive biomarker in this setting, but is a marker of poor prognosis </plain></SENT>
</text></document>